[
    {
        "name": "KRAS mutation",
        "type": "Oncogene mutation",
        "effect": "Antagonistic",
        "clinicalImplication": "Reduces efficacy of BRAF inhibitors; typically mutually exclusive with BRAF V600E",
        "frequencyOfCooccurrence": "Rare (<1%)"
    },
    {
        "name": "PIK3CA mutation",
        "type": "Oncogene mutation",
        "effect": "Synergistic",
        "clinicalImplication": "May contribute to resistance to BRAF inhibitors; combination therapy targeting both pathways may be beneficial",
        "frequencyOfCooccurrence": "10-15% of BRAF-mutant CRC"
    },
    {
        "name": "Microsatellite Instability (MSI-H)",
        "type": "Molecular phenotype",
        "effect": "Variable",
        "clinicalImplication": "MSI-H tumors with BRAF V600E may respond better to immunotherapy than MSS BRAF-mutant tumors",
        "frequencyOfCooccurrence": "~30% of BRAF-mutant CRC"
    }
]